CIBC Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-10,064
Closed -$95K 1351
2022
Q1
$95K Hold
10,064
﹤0.01% 1461
2021
Q4
$116K Sell
10,064
-494
-5% -$5.5K ﹤0.01% 1471
2021
Q3
$101K Buy
+10,558
New +$108K ﹤0.01% 1426
2021
Q1
Sell
-9,917
Closed -$229K 1344
2020
Q4
$229K Buy
+9,917
New +$203K ﹤0.01% 1051

Other funds holding FOLD

CIBC Asset Management's FOLD Position: Q2 2022 in Review

CIBC Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2022, closing a stake of 10,064 shares — an estimated $95K sold.

CIBC Asset Management first reported a position in FOLD in Q4 2020 and held it in 4 quarters. The position peaked at $229K in Q4 2020. 212 funds tracked by Wall St. Rank hold FOLD as of Q2 2022.

  • CIBC Asset Management reported no remaining Amicus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CIBC Asset Management sold 10,064 Amicus Therapeutics shares in Q2 2022, an estimated $95K.
  • CIBC Asset Management first reported a position in Amicus Therapeutics in Q4 2020 and held it in 4 quarters.
  • CIBC Asset Management's Amicus Therapeutics position peaked at $229K in Q4 2020.
  • 212 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2022.

Based on CIBC Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.